Inivata

Inivata develops blood tests using circulating tumour DNA to improve cancer care.

Cambridge, UK—Founded 2014—Website

£43.8MTotal raised

Inivata is a clinical cancer genomics company that utilises circulating tumour DNA analysis from blood samples to improve cancer testing and treatment.

Team

Clive Morris

Chief Executive Officer

Clive brings executive experience from Inivata Limited, alongside board and committee roles at Wheatsheaf Group and Medicines Discovery Catapult.

Nitzan Rosenfeld

Chief Scientific Officer

Investors

Series B28 March 2019
£39.8M
RV
RT VenturesLead
WP
Woodford Patient Capital Trust
IP Group
Cambridge Innovation CapitalFollow-on
J&
Johnson & Johnson Innovation – JJDC
1 December 2014
£4.0M
II
Imperial Innovations
Cambridge Innovation Capital
J&
Johnson & Johnson Development Corporation

Funding history

Series B28 March 2019

£39.8M

Inivata raises £39.8m in Series B funding led by RT Ventures

The financing round was led by RT Ventures and will support the US commercial roll-out of the company test.

1 December 2014

£4.0M

Inivata raises up to £4m from Imperial Innovations, Cambridge Innovation Capital and Johnson & Johnson Development Corporation to advance cancer blood tests.

The funding was provided by Imperial Innovations, Cambridge Innovation Capital and Johnson & Johnson Development Corporation.